Phase II study of pembrolizumab plus nab-paclitaxel in Hormone Receptor–positive, HER2- negative metastatic breast cancer: clinical and molecular insights into response
Abstract
Abstract Purpose We investigate the addition of PD-1 blockade to chemotherapy in HR + MBC to assess efficacy, safety, and changes in the tumor microenvironment utilizing serial tumor biopsies. Methods Single-arm phase 2 clinical trial (NCT02752685) of 20 HR+/HER2- MBC patients received nab-paclitaxel (100mg/m2 IV d1/8, q 3 weeks) and pembrolizumab (200mg IV d1, q 3 weeks, starting with cycle 2). Primary endpoint: best overall response rate (BORR) by RECIST v1.1; secondary endpoints: safety, progression free survival (PFS), duration of response (DOR), and overall survival (OS). Changes in PD-L1 score, stromal tumor-infiltrating lymphocytes (TIL), T-Cell Receptor (TCR) sequence, gene expression, and quantitative multiplex immunofluorescence (qMIF) were evaluated serially during treatment. Results The BORR for partial response (PR) was 26.3% (5/19). Median (m) PFS was 4.1 months (mo) (95% CI 2.2–12.5), mOS was 15.7 mo (95% CI 10.0- NA), and mDOR was 5.6 mo (3.9–52.7). 14 patients experienced one or more grade 3 or higher adverse events (AEs), the most common being anemia, fatigue, diarrhea, and neutropenia, and there were no grade 5 AEs. Longitudinal spatial qMIF and transcriptomic profiling indicated that tumor immune remodeling and proliferative programs shape treatment response, with adaptive immune activation alone being insufficient, supporting combination approaches targeting tumor cell-cycle control and immune competence. No predictive biomarkers emerged, however higher T-cell fraction at baseline was associated with OS (p = 0.0009). Conclusions Chemoimmunotherapy was efficacious with manageable toxicity profile. Importantly, responses were seen in patients previously treated with CDK 4/6 inhibitors. Further research is needed for predictive biomarkers in HR+/HER2- MBC to checkpoint blockade.